Showing results (131-140 of 307) with videos related to
Sort By:
Pageof 31
BMC Neurology|August 20, 2016
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotensionClément François, Gerald J Rowse, L Arthur Hewitt, et al.Neurology and Therapy|April 17, 2021
Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and DyskinesiaShyamal H Mehta, Rajesh Pahwa, Caroline M Tanner, et al.Neuropsychiatric Disease and Treatment|November 10, 2009
Sleep disorders in Parkinson's diseaseIsrat Jahan, Robert A Hauser, Kelly L Sullivan, et al.Plos One|December 17, 2019
Higher neuron densities in the cerebral cortex and larger cerebellums may limit dive times of delphinids compared to deep-diving toothed whalesSam H Ridgway, Robert H Brownson, Kaitlin R Van Alstyne, et al.Clinical Neuropharmacology|June 15, 2006
Topiramate-induced psychosis in patients with essential tremor: report of 2 casesTheresa A Zesiewicz, Archer Tullidge, Jonathan Tidwell, et al.Neurology and Therapy|May 23, 2021
Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and DyskinesiaRobert A Hauser, Shyamal H Mehta, Daniel Kremens, et al.The International Journal of Neuroscience|January 20, 2011
Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's diseaseRobert A Hauser, Heinz Reichmann, Mark Lew, et al.Clinical Neuropharmacology|June 15, 2006
The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin statusTheresa A Zesiewicz, Lynn Wecker, Kelly L Sullivan, et al.Parkinsonism & Related Disorders|July 15, 2005
Levetiracetam for the treatment of generalized dystoniaKelly L Sullivan, Robert A Hauser, Elan D Louis, et al.Journal of Medical Economics|December 29, 2015
Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial dataClément François, Robert A Hauser, Samuel Aballéa, et al.Pageof 31